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Background: Cytogenetic evaluation of products of conception (POC) for chromosomal abnormalities is central to
determining the cause of pregnancy loss. We compared the test success rates in various specimen types and the
frequencies of chromosomal abnormalities detected by G-banding analysis with those found by Oligo-SNP chromosomal
microarray analysis (CMA). We evaluated the benefit of CMA testing in cases of failed culture growth.
Methods: Conventional cytogenetic results of 5457 consecutive POC specimens were reviewed and categorized as
placental villi, fetal parts, and unspecified POC tissue. The CMA was performed on 268 cases. Of those, 32 cases had
concurrent G-banding results. The remaining 236 cases included 107 cases with culture failure and 129 cases evaluated
by CMA alone.
Results: The overall POC culture success rate was 75%, with the lowest for fetal parts (37.4%) and the highest for
placental villi (81%). The abnormality rate was 58% for placental villi, but only 25% for fetal parts. Of the abnormalities
detected, the most common were aneuploidies, including trisomy 16, triploidy, monosomy X, trisomy 22, trisomy 21 and
trisomy 15, while the least encountered aneuploidies were trisomy 1, trisomy 19 and monosomies (except monosomy
21). Overall, POC specimens studied by CMA were successful in 89.6% of cases and yielded a 44.6% abnormality rate.
Conclusions: Placental villi yielded higher rates of culture success and a higher percentage of abnormal karyotypes than
did other specimen types. The Oligo-SNP CMA method has demonstrated a viable alternative to the G-banding method
in view of its advantages in detection of submicroscopic genomic aberrations, shorter turnaround time due to elimination
of time required for culture and a higher test success rate.
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Spontaneous pregnancy loss is a common clinical occur-
rence. Many studies have demonstrated that 50% of all fer-
tilized eggs die and spontaneously abort, usually before
the pregnancy is recognized. Among women who know
they are pregnant, the miscarriage rate is 15-20% [1,2].
Most miscarriages occur during the first 7 weeks of
pregnancy. Aneuploidy and unbalanced chromosomal ab-
normalities account for 50-60% of fetal loss during this
period [3-6]. Cytogenetic evaluation of the products of
conception (POC) is central in determining the cause of* Correspondence: Arturo.L.Anguiano@questdiagnostics.com
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unless otherwise stated.pregnancy loss and aids in the estimation of recurrence
risk and in counseling for subsequent pregnancies. How-
ever, there are many challenges in cytogenetic evaluation.
Recent studies have demonstrated that the type of tissue
received by a cytogenetics laboratory is critical for the suc-
cess of cell growth in culture and the subsequent karyo-
type analysis [5,7]. Our observations and those of others
[5,7] demonstrate that the average culture success rate
varies by tissue type with placental villi being the highest
(>80%) and fetal parts being the lowest (<40%). Placental
decidua almost always represents maternal tissue and is
thus not an appropriate specimen type for study [7-10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Placental villi after cleaning (400x magnification).
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analysis method is limited to obtaining results of nu-
merical abnormalities and gross structural rearrange-
ments. In contrast, CMA has a much higher resolution,
detecting submicroscopic rearrangements as small as
50 kb by examining extracted DNA from the uncultured
cells of fresh POC specimens [8,11-18]. A recent report
entitled “rescue karyotyping” using chromosomal micro-
array analysis (CMA) on the DNA extracted from archived
paraffin-embedded tissue after a procedure of dilation &
curettage (D&C), has further proven that the DNA-based
array method is effective enough to obtain critical fetal
cytogenetic information from a prior loss, even if the loss
occurred years earlier, in an assessment of couples with re-
current pregnancy loss [19]. In this study, we evaluated
culture success rates in various types of POC specimens
and the frequencies of chromosomal abnormalities by G-
banding analysis in 5457 consecutive POC samples. We
also performed an Oligo-SNP chromosomal microarray
analysis (CMA) on 268 clinical cases in an attempt to
compare test success rates and abnormality rates between
the two methods.
Methods
Detection of chromosome abnormalities by the
G-banding method
When received, the POC specimens were first placed
under a dissecting microscope for gross examination.
Cases with specimens that contained only placental de-
cidua were excluded from the study since placental de-
cidua is most likely maternal in origin. The specimens
were then carefully dissected, and rinsed 3x in culture
medium to remove maternal deciduous tissue before set-
up for culture (Figures 1 and 2). Because of our extensive
experience in processing chorionic villi samples (CVS)
[20], we expect the risk for maternal cell contaminationFigure 1 Placental villi before cleaning (400x magnification).
Please note that there is a piece of maternal deciduous tissue
attached to the villi (at the upper center).(MCC) to be minimal for specimens so processed. A total
of 5457 consecutive POC specimens were then catego-
rized as placental villi, fetal parts, and unspecified POC tis-
sue (e.g., chorionic membrane, umbilical cord), cultured,
harvested and analyzed by conventional cytogenetic ana-
lysis (the G-banding) method as described elsewhere. For
specimens containing placental villi and other types of tis-
sue, only placental villi were used for culture.
Detection of genomic aberrations by the oligo-SNP
chromosomal microarray
Each of the POC specimens was carefully examined, dis-
sected and cleaned in the same way as mentioned above
to remove maternal deciduous cells to reduce the risk of
maternal cell contamination. Cases with specimens that
contained only placental decidua were excluded from the
study. A total of 268 clinical cases were analyzed by Oligo-
SNP CMA (oligonucleotide, single nucleotide polymorph-
ism, Affymetrix™ CytoScan HD, Affymetrix™, Inc., Santa
Clara, California, USA). Among the cases studied, 32
cases were performed by both G-banding and array
methods; 107 cases without a cytogenetic result due to
failed culture were studied thereafter by the CMA
method. The remaining 129 cases were performed by
the array method alone. This Oligo-SNP CMA method
used a microarray containing over 2.67 million probes,
including 1.9 million copy number probes and 750
thousand SNP probes. The overall average inter-probe
distance is 1,150 base pairs. Thresholds for genome-
wide screening are set at >200 kb for gains, >50 kb for
losses, and >10 Mb for regions of homozygosity (ROH).
Results
The overall culture success rate for POC tissues was 75%
(4092/5457), lowest for fetal parts (382/995; 38.4%) and
highest for placental villi (2907/3567; 81%). The abnormal-
ity rate was 58% for placental villi, but only 25% for fetal
Figure 3 Autosomal trisomies (n = 1241) breakdown
by chromosome.
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common were aneuploidies including trisomy 16 (14.7%),
triploidy (14%), monosomy X (13%), trisomy 22 (8.9%), tri-
somy 21 (8.6%), and trisomy 15 (7.3%), while the least en-
countered aneuploidies were trisomy 1, trisomy 19 and
autosomal monosomies (except monosomy 21) (Table 1
and Figure 3).
In the Oligo-SNP CMA study series, the 32 cases ana-
lyzed by both G-banding and the array method demon-
strated 81% (26/32) concordance, confirming all unbalanced
abnormalities and detecting additional abnormalities in 5
cases not identified by the G-banding method, which in-
cluded one case with a cryptic unbalanced (1;10) trans-
location (note: parental studies have been requested to
determine its origin) and 4 cases with a VOUS result (vari-
ant of unknown significance). However, there was also
one case that was reported as normal by the array
method, but actually had a balanced (14;15) transloca-
tion (Table 2). Among the 107 cases with failed culture,
this array method was successful in 84% (90/107) of cases
and yielded a 39% (35/90) abnormality rate. In addition,
one case with no copy number change was found to have
segmental UPD 16 (41.7 Mb) (Table 2 & Figure 4). In the
remaining 129 cases studied by Oligo-SNP CMA alone,
testing was successful in 91% (118/129) of cases, yielded
a 51% (60/118) abnormality rate and detected one case
involving mosaic segmental UPD 18 (46.6 Mb) (Table 2
& Figure 5). Therefore, overall, POC specimens studied
by CMA were successful in 89.6% (240/268) of cases
and yielded a 44.6% (107/240) abnormality rate.Discussion
The distribution of chromosome aneuploidies, particu-
larly the trisomies, observed in this study was similar to
those of previous studies [5,21]. The least encountered
aneuploidies were trisomy 1, trisomy 19 and mono-
somies (except monosomy 21). Non-mosaic trisomy 1
appears to be incompatible with even rudimentary fetal
development and correlates with a diagnosis of blighted
ovum [22-24]. There was only one case of trisomy 19Table 1 Frequency of chromosome abnormalities in POC
with abnormal karyotypes (n = 1872)
Type Approximate proportion of
abnormal karyotypes
Aneuploidy
Autosomal trisomy 1236 (66%)
Autosomal monosomy 19 (1%)
45, X 243 (13%)
Triploidy 262 (14%)
Tetraploidy 75 (4%)
Other (inversions, translocations, etc.) 37 (2%)documented in our study series; there were no cases of tri-
somy 19 reported in previous first trimester studies of
abortuses [25]. We suspect that trisomy 19, like trisomy 1,
is embryonic lethal due to its high gene content [www.
ensembl.org, v36]. With the exception of monosomy 21,
we rarely observed autosomal monosomy in our study.
We hypothesized that this may reflect the high lethality of
gene insufficiency in early fetal development [1,2].
Placental villi yielded higher rates of culture success and
a higher percentage of abnormal karyotypes than did other
specimen types. However, a very small fraction of these
abnormal karyotypes may be due to confined placental
mosaicism (CPM) [20]. Our findings further support the
request for placental villi, whenever possible, for POC
chromosome studies. The higher abnormality rate in pla-
cental villi may have been the result of a higher percentage
of viable abnormal cells available for culture. The lower
abnormality rate in fetal parts may be due to maceration
of abnormal fetuses before the time of miscarriage, caus-
ing cells to be less likely to grow in culture. We hypothe-
sized that fetal parts from a chromosomally normal fetus
tend to have a better chance to grow in culture and yield a
chromosome result. As villi have the highest culture suc-
cess rate, clinicians should be encouraged to submit pla-
cental villi whenever possible [5,7].
Our present study demonstrates that the DNA-based
microarray technologies overcome many of the limitations
of conventional cytogenetic analysis on POC specimens
and enhance the test success rate (89.6% vs. 75%), the turn-
around time (8 days vs.14 days) and the detection of sub-
microscopic chromosomal aberrations. Furthermore, the
CMA approach uses extracted DNA, instead of cultured
cells, which eliminates the considerable amount of time re-
quired for cell culture. CMA is not capable of detecting
balanced rearrangements such as translocations, inversions
and insertions; however, these types of abnormalities are
unlikely to be related to the cause of a miscarriage. Overall,
the oligo-SNP CMA method possesses a higher resolution
in detecting unbalanced genomic aberrations than the
Table 2 The Oligo-SNP CMA results obtained from the 268 clinical cases
Microarray
Normal Abnormal VOUS* Failed Total
Karyotyping (chromosomes) Normal 19 1(a) 4(b) 0 24
Abnormal 1(c) 7 0 0 8
No growth 55 30(d) 5 17 107
CMA alone 58 49(e) 11 11 129
Total 133 87 20 28 268
(a) arr[hg19] 1p36.33p36.21(849,466-15,970,926)x1, 10q26.2q26.3(129,968,527-135,427,143)x3.





(d) One case with segmental UPD 16
[arr[hg19] 16p13.3p12.3(89,560-20,228,889)x2 hmz,
16q21q23.3(62,222,293-83,741,752)x2 hmz].
(e) One case with a Xp21.1 deletion, trisomy 16, and mosaic segmental UPD 18.
[ arr[hg19] Xp21.1(31,746,498-31,987,991)x1,(16)x3,(18)x2-3,
18p11.31q12.1(5,218,469-29,237,765)hmz, 18q21.31q23(55,397,870-78,014,582)hmz].
*VOUS – Variant of unknown significance.
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based microarrays can detect polyploidy (e.g., triploidy)
and uniparental isodisomy (UPD) [26-28].
With the advent of the more sensitive DNA-based CMA
technologies, the conventional cytogenetic analysis might
be replaced by the new quantitative, microarray-basedFigure 4 A case with segmental UPD 16 was detected by Oligo-SNP Cmethods in the near future. However, as with any new
technology, the microarray methods need to be carefully
validated. The relatively expensive and sophisticated tech-
nical requirements may slow down the general adoption
of the CMA [16,18,29,30]. In their recent studies, Baxter
et al. (2013) proposed an integrated strategy to performMA.
Figure 5 A case with a Xp21.1 deletion, trisomy 16 and mosaic segmental UPD 18 was detected by Oligo-SNP CMA.
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in situ hybridization) with reflex array approach [31]. In this
proposal, the authors advocated FISH analysis to detect the
common abnormalities such as aneuploidy of chromo-
somes 13, 18, 21, X or Y with a reflex to CMA when FISH
was normal. Of 100 abnormal cases they studied, they
found that 46% were detectable by a FISH aneuploidy panel
alone, leaving only 54% of the abnormal cases to be further
studied by the relatively expensive microarray method.
However, our FISH experience did not support such a strat-
egy. In our experience, the FISH test failure rate could be
as high as 28%. It was noted that the slides prepared for
FISH from the macerated POC specimens were mostly
poor in quality, thus leading to an even higher test failure
rate than the conventional G-banding method (28% vs.
25%). Furthermore, this FISH with reflex array approach
can be as costly as the CMA method, because many FISH
probes have to be used in the study.
Conclusion
Placental villi yielded a higher rate of culture success and a
higher percentage of abnormal karyotypes than did other
specimen types. Specimens containing only placental de-
cidua most likely represent maternal deciduous tissue and
are not recommended for POC studies. We believe that
CMA is a viable alternative to the conventional G-bandingmethod, even though CMA is relatively costly. Significant
benefits of CMA, such as detection of submicroscopic
genomic aberrations, elimination of time required for cell
culture, a shorter turnaround time, a lower test failure rate
and the robust nature of CMA, have been well demon-
strated. In addition, CMA can be also performed to obtain
a cytogenetic result on archived paraffin-embedded POC
tissues [19]. At present, we routinely offer the Oligo-SNP
CMA method to clients whenever there is a culture failure
and a back-up specimen is still available. In the future, as
the cost of CMA decreases, CMA testing may be the first
choice for cytogenomic evaluation of POC specimens.
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